TRMT9B: A Potential Drug Target and Biomarker for ALS (G57604)

Target Name: TRMT9B

NCBI ID: G57604

TRMT9B

TRMT9B: A Potential Drug Target and Biomarker for ALS

Introduction

Amyloidosis is a neurodegenerative disease characterized by the accumulation of amyloid peptides and neurofibrillary tangles in the brain. It is a progressive and fatal disease that primarily affects approximately 50 million people worldwide, affecting older adults. The most common cause of amyloidosis is the inheritance of the genetic mutation E62432, which encodes for the transthyretin receptor type II (TTR) gene. Another potential cause of amyloidosis is the mutation E62431, which encodes for the transthyretin receptor type I (TTR1) gene. In both cases, the accumulation of amyloid peptides and neurofibrillary tangles in the brain leads to the development of the disease.

TRMT9B: The Putative Cause of TRANSPHYRETIN receptor Type II Methylation

TRMT9B is a gene that encodes for the tRNA methyltransferase 9B protein. The tRNA methyltransferase is an enzyme that modifies the methylation of the promoter region of a gene. Methylation of the promoter region can inhibit gene transcription and contribute to the regulation of gene expression . The TRMT9B gene has been implicated in the development of amyloidosis due to the mutation E62432.

The TRMT9B gene was identified as a potential drug target and biomarker for amyloidosis due to its association with the development of the disease. Several studies have shown that TRMT9B is involved in the regulation of gene expression and has been shown to be expressed in the brains of individuals with amyloidosis. Additionally, several studies have shown that inhibition of TRMT9B has led to the reduction in the amount of amyloid peptides and neurofibrillary tangles in the brains of individuals with amyloidosis.

TRMT9B as a Drug Target

Drugs that target TRMT9B have the potential to treat amyloidosis by reducing the amount of amyloid peptides and neurofibrillary tangles in the brain. Several studies have shown that inhibition of TRMT9B has led to the reduction in the amount of amyloid peptides and neurofibrillary tangles in the brains of individuals with amyloidosis.

One of the potential benefits of targeting TRMT9B is that it can be used as a biomarker to diagnose amyloidosis. The TRMT9B gene has been shown to be expressed in the brains of individuals with amyloidosis, and inhibition of TRMT9B has been shown to reduce the amount of amyloid peptides and neurofibrillary tangles in the brains of individuals with amyloidosis. This could make TRMT9B a useful biomarker for the diagnosis of amyloidosis.

Another potential benefit of targeting TRMT9B is that it can be used to treat amyloidosis by reducing the amount of amyloid peptides and neurofibrillary tangles in the brain. Several studies have shown that inhibition of TRMT9B has led to the reduction in the amount of amyloid peptides and neurofibrillary tangles in the brains of individuals with amyloidosis. This could make TRMT9B a useful target for the development of drugs that treat amyloidosis.

TRMT9B as a Biomarker

TRMT9B has also been shown to be expressed in the brains of individuals with amyloidosis, which makes it a potential biomarker for the disease. The TRMT9B gene has been shown to encode for a protein that is involved in the regulation of gene expression. Additionally, several studies have shown that TRMT9B has been shown to

Protein Name: TRNA Methyltransferase 9B (putative)

Functions: May modifie wobble uridines in specific arginine and glutamic acid tRNAs. Acts as a tumor suppressor by promoting the expression of LIN9

The "TRMT9B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRMT9B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets